Cellectis Company Contacts

Cellectis

https://www.cellectis.com/
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 24 years of expertise... Read More
Contacts

Country

France

City

Paris

Headquarters

Paris, FR

Profile

Founded

1999

Industry

Biotechnology Research

Size

51 - 200

Specialties

Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, off-the-shef CART therapies

Funding

Total Rounds

8

Last Round

Tue Oct 31 2023

Last Round Series

Post IPO equity

Last Round Raised

$ 80,000,000